Evidence map›Paper›PMID 28959312›Full record

ArticleIranian journal of biotechnology2016

Sodium Butyrate and Valproic Acid as Splicing Restoring Agents in Erythroid Cells of β-Thalassemic Patients.

Mahmoud Shekari Khaniani, Mahdieh Tagizadeh, Abbasali Hosseinpour Feizi, Sima Mansoori Derakhshan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mahmoud Shekari KhanianiDepartment of Hematology Oncology Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Mahdieh TagizadehDepartment of Hematology Oncology Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Abbasali Hosseinpour FeiziDepartment of Medical Genetics, Tabriz University of Medical Science, Tabriz, Iran.
Sima Mansoori DerakhshanDepartment of Hematology Oncology Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundβ-Thalassemia is a common autosomal recessive disorder in human caused by a defect in

objectivesThe aim of this study was to investigate the effects of NaBu, isoBu and VPA drugs on restoration of splicing of IVSI-110 β-Thalassemia pre-mRNA in human. MATERIALS AND

methodsPrimary erythroid cells derived from IVSI-110 β-Thalassemia patients were cultured ex vivo and differentiated in the presence of 0.5 and 1 mM of Na-Butyrate (NaBu), 0.5 mM Isobutyramide (isoBu) and 100 μM Valproic acid (VPA). RT- PCR analysis was used to evaluate the effect of the drugs in correction of normal splicing in bglobin mRNAs.

resultsFollowing treatment with NaBu, isoBu and VPA, the level of normal

conclusionsThe results highlighted the therapeutic potential of splicing modulation for genetic diseases caused by splicing mutations.

Indexed as

IVSI-110 mutationSplicing modulationSR proteinsβ-Thalassemia

Identifiers

PMID28959312
PMCPMC5435016
OpenAlexW2282667942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.